Advanced Nuclear Medicine Ingredients (ANMI) has signed an agreement to license a clinical-stage SPECT radiopharmaceutical for prostate cancer imaging from the Mexican Instituto Nacional de Investigaciones Nucleares (ININ).
The agreement covers technetium-99m-EDDA/HYNIC-Lys(NaI)-Urea-Glu (Tc-99m iPSMA). ANMI is a wholly owned subsidiary of Telix Pharmaceuticals, which is also developing illumet, a gallium-68 (Ga-68) prostate-specific membrane antigen (PMSA) kit.
Based on evaluations by ININ and its collaborators, Tc-99m iPSMA with SPECT/CT has high sensitivity for the detection of prostate cancer lesions. The images obtained with Tc-99m iPSMA were qualitatively and semiquantitatively similar to those from Ga-68 PSMA-11 with PET/CT, according to the companies.
ANMI and Telix believe Tc-99m iPSMA has clinical and commercial potential for evaluating primary disease and metastases in patients who do not have access to PET imaging.
